Aesthetic of ugliness in the art of painting between 17th century and early 20th century
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
Hereby this thesis titled "Aesthetic of Ugliness in the Art of Painting Between 17th Century and Early 20th Century" investigates the paintings that contain ugliness in them. The main focus is to show and discuss paintings that include ugly content or figures to reveal the fact that in the History of Fine Arts, since the 17th century, ugliness is used as a conceptual and aesthetic parameter. In this context, to understand and to define ugliness; beauty is explained first in chapter II and III, both in philosophy and in art. In chapter IV, ugliness is described and exemplified in accordance to the art periods. In chapter V, the explanations of the selected examples of paintings that mention ugly in them from 17th century starting with Baroque and until the early 20th century ending with New Objectivity is explained. As a result, the aim is to show the importance of ugliness in the art of painting.
Author
Elif Erdemgil
Institution
How to Cite
Elif Erdemgil (Master Thesis). Aesthetic of ugliness in the art of painting between 17th century and early 20th century, 2021, Yeditepe University.
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)